Recent clinical trials have shown that sodium glucose co-transport 2 (SGLT2) inhibitors have
dramatic beneficial cardiovascular outcomes. These include a reduced incidence of …

Heart failure with preserved ejection fraction (HFpEF) represents one of the greatest
challenges facing cardiovascular medicine today. Despite being the most common form of …

Periodontal and cardiovascular disease are both major health issues. Poor oral health has
long been associated with the development of systemic diseases, with the typical example …

Excessive feeding is associated with an increase in the incidence of chronic metabolic
diseases, such as obesity, insulin resistance, and type 2 diabetes. Metabolic disturbance …

Inflammation is a key mechanism of cardiovascular diseases. It is an essential component of
atherosclerosis and a significant risk factor for the development of cardiovascular events. In …

Iron deficiency is a major heart failure co‐morbidity present in about 50% of patients with
stable heart failure irrespective of the left ventricular function. Along with compromise of daily …

Heart failure with preserved ejection fraction (HFpEF) is increasing in prevalence worldwide,
already accounting for at least half of all cases of heart failure. As most patients with HFpEF …

Abstract Background Mesenchymal precursor cells (MPCs) are allogeneic, immunoselected
cells with anti-inflammatory properties that could improve outcomes in heart failure with …

The complex physiological signal transduction networks that respond to the dual challenges
of inflammatory and oxidative stress are major factors that promote the development of …

To date, 3 clinical trials have shown symptomatic benefit from the use of intravenous (IV) iron
in patients with heart failure (HF) with low serum iron. This has led to recommendations in …